Phase
Condition
N/ATreatment
Intravenous dobutamine 12.5 mcg/kg/min
Intravenous dobutamine 10 mcg/kg/min
Intravenous dobutamine 7.5 mcg/kg/min
Clinical Study ID
Ages < 72 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Born with up to 32(+6) weeks gestation
Presence of hemodynamic insufficiency, defined as SVC flow <51 ml/kg/min.
Provision of signed and dated informed consent form by father/mother or legallydesignated representative, which can be given antenatally.
Exclusion
Exclusion Criteria:
Neonates considered non-viable, with a clinical decision not to provide life support
Infants with severe congenital hydrops fetalis needing chest or peritoneal drainagebefore recruitment
Infants already on dobutamine treatment
Infants with congenital malformations likely to affect cardiovascular adaptation (including: congenital diaphragmatic hernia, gastroschisis or congenital heartdefects)
Infants with chromosomal anomalies
Lack of parental signed informed consent
Study Design
Connect with a study center
Hospital Universitario 12 de Octubre
Madrid, 28041
SpainActive - Recruiting
Hospital Universitario La Paz
Madrid, 28046
SpainActive - Recruiting
Hospital Universitario Quironsalud
Madrid, 28002
SpainActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.